Thoroughly updated chapters, incorporating new therapeutic approaches and recently marked drugs, such as long acting GLP-1 receptor agonists (Semaglutide) and SGLT-2 inhibitors (Dapagliflozin) for diabetes, neprilysin inhibitor (sacubitril) and SGLT-2 inhibitors for CHF, Orexin antagonists (Suvorexant) as hypnotic, Rho-Kinase inhibitor (Netarsudil) for glaucoma, adrenergic beta-3 agonist (Mirabegron) for overactive bladder, PCSK9 inhibitor (Inclisiran) as long acting hypocholesterolemic, CGRP receptor antagonists (Rimegepant) for migraine, PDE-4 inhibitor (Roflumilast) for COPD, and many others. \n

\n
• Latest therapeutic and prophylactic regimens recommended under the National Health Programs for MDR/XDR-tuberculosis, leprosy, HIV, malaria, kala-azar, filariasis, viral hepatitis, etc.
\n
• Drugs and vaccines for COVID-19 and the latest AIIMS/ICMR guidelines for management of COVID.
\n
• Pharmacovigilance program of India.
\n
• Evidence based medicine with authenticated reference to latest therapeutic guidelines from WHO; ACC/AHA; ISH; NICE; SIGN; Cochrane reviews, meta analysis and landmark clinical trials.
\n
• The WHO classification of antibiotics into `AWaRe” (Access, Watch, Reserve) groups.
\n
• A Separate chapter on alcohols, drug dependence and drugs of abuse.
\n
• A new chapter on environmental toxicology, poisonings; snake/dog bites and scorpion/bee stings.
\n
• Chapterwise listing of abbreviations for user convenience.
\n
• Several new figures, flow charts, tables and highlight boxes.
\n
• Full coverage of competency-based pharmacology curriculum of NMC for graduate medical students.
\n